| Date Filed | Type | Description |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results |
| 08/04/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/21/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 07/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/02/2023 |
SC 13D/A
| SR ONE CAPITAL MANAGEMENT, LLC reports a 8.2% stake in Arcellx, Inc. |
| 05/31/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/25/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/19/2023 |
SC 13D/A
| SR ONE CAPITAL MANAGEMENT, LLC reports a 9.4% stake in Arcellx, Inc. |
| 05/11/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/11/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/09/2023 |
10-Q/A
| Quarterly Report for the period ended March 31, 2023 [amend] |
| 05/08/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 05/08/2023 |
S-3ASR
| Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers: |
| 05/08/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/08/2023 |
8-K
| Quarterly results|
Docs:
|
"Arcellx Provides First Quarter Financial Results REDWOOD CITY, Calif., May 8, 2023 /PRNewswire/ -- Arcellx, Inc. , a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported financial results for the first quarter ended March 31, 2023. “Delivering our novel CAR-T therapy to multiple myeloma patients is at the heart of our mission,” said Rami Elghandour, Arcellx’s Chairman and Chief Executive Officer. “With the closing of our Kite partnership in the first quarter, we believe we are well capitalized to fund our operations through the first half of 2025. We remain laser-focused on key drivers of our business which include completing enrollment of iMMagine-1, i..." |
|
| 05/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/24/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/19/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/14/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/29/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/29/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 4.7% stake in Arcellx, Inc. |
| 02/14/2023 |
SC 13G
| PERCEPTIVE ADVISORS LLC reports a 5.5% stake in Arcellx, Inc. |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
SC 13G/A
| BlackRock Inc. reports a 4.9% stake in ARCELLX INC |
| 02/08/2023 |
SC 13G
| BlackRock Inc. reports a 5% stake in ARCELLX INC |
| 02/06/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/06/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 01/30/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 01/24/2023 |
SC 13D/A
| New Enterprise Associates 15, L.P. reports a 10.8% stake in Arcellx, Inc. |
| 01/03/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 12/16/2022 |
8-K
| Quarterly results |
| 12/12/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
|